Update on the Management of Pancreatic Cancer in Older Adults

Current Oncology Reports

Volumn 18, Issue 10, 2016, Pages

  Lee, Shin Yin ^a   Sissoko, Moussa ^b   Hartshorn, Kevan L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHARLESTON AREA MEDICAL CENTER   (United States)

Author keywords

Chemoradiation; Chemotherapy; Comprehensive geriatric assessment; Frailty scores; Geriatric oncology; Novel therapies; Older adults; Pancreatic adenocarcinoma; Radiation; Surgery; Symptom management; Toxicity scores; Update

Indexed keywords

CAPECITABINE; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IRINOTECAN; NIVOLUMAB; OXALIPLATIN; PACLITAXEL; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; AGE DISTRIBUTION; AGING; BONE MARROW SUPPRESSION; BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTINUOUS INFUSION; DIARRHEA; FATIGUE; FRAIL ELDERLY; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; HUMAN; LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA; METASTASIS; NEUROPATHY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; STOMATITIS; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; AGED; CHEMORADIOTHERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PATIENT SELECTION; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; GERIATRIC ASSESSMENT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84982840502     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-016-0547-4     Document Type: Review

References (105)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.
2. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER website, April 2015. [Internet]. [cited 2016 Feb 7]. Available from: http://seer.cancer.gov/csr/1975_2012/.
3. Yancik R. Population aging and cancer: a cross-national concern. Cancer J Sudbury Mass. 2005;11:437–41.
4. Hanson LC, Muss HB. Cancer in the oldest old: making better treatment decisions. J Clin Oncol. 2010;28:1975–6.
5. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–49.
6. Cancer of the pancreas—SEER Stat Fact Sheets [Internet]. [cited 2016 Jan 3]. Available from: http://seer.cancer.gov/statfacts/html/pancreas.html.
7. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:3457–65.
8. Zeng C, Wen W, Morgans AK, Pao W, Shu X-O, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. JAMA Oncol. 2015;1:88–96.
9. He W, Zhao H, Chan W, Lopez D, Shroff RT, Giordano SH. Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Surgery. 2015;158:1226–34.
10. Amin S, Lucas AL, Frucht H. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis. Pancreas. 2013;42:249–53.
11. Jacobson SD, Alberts SR, O’Connell MJ. Pancreatic cancer in the older patient. Oncol Williston Park N. 2001;15:926–32.
12. Parmar AD, Vargas GM, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery. 2014;156:280–9.
13. Foster JA, Salinas GD, Mansell D, Williamson JC, Casebeer LL. How does older age influence oncologists’ cancer management? Oncologist. 2010;15:584–92.
14. Lipitz-Snyderman A, Sepkowitz KA, Elkin EB, Pinheiro LC, Sima CS, Son CH, et al. Long-term central venous catheter use and risk of infection in older adults with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:2351–6.
15. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:4626–31.
16. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–6.
17. Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliu J. Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016;22:764–75.
18. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer. 2008;98:517–22.
19. Chen H, Cantor A, Meyer J, Beth Corcoran M, Grendys E, Cavanaugh D, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 2003;97:1107–14.
20. Ramjaun A, Nassif MO, Krotneva S, Huang AR, Meguerditchian AN. Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. J Geriatr Oncol. 2013;4:271–81.
21. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:1824–31.
22. Puts MTE, Santos B, Hardt J, Monette J, Girre V, Atenafu EG, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014;25:307–15.
23. Kalsi T, Babic-Illman G, Ross PJ, Maisey NR, Hughes S, Fields P, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112:1435–44. This study showed that geriatrician-delivered geriatric assessment improves completion rates of chemotherapy, fewer treatment modifications, and decreased toxicity.
24. Dale W, Hemmerich J, Kamm A, Posner MC, Matthews JB, Rothman R, et al. Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014;259:960–5. This is a prospective outcome study which showed that the geriatric assessment prospectively and independently predicted adverse surgical outcomes in older patients undergoing pancreaticoduodenectomy.
25. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:2595–603.
26. Luciani A, Biganzoli L, Colloca G, Falci C, Castagneto B, Floriani I, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol. 2015;6:272–9.
27. Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:2166–72.
28. Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015;26:288–300. This is the latest SIOG recommendation on screening tools for frailty in older cancer patients. It is also a good systemic review of studies comparing various screening tools with the comprehensive geriatric assessment and with each other.
29. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86.
30. Goodman MD, Saif MW. Adjuvant therapy for pancreatic cancer. JOP J Pancreas. 2014;15:87–90.
31. Matsuda Y, Ishiwata T, Yachida S, Suzuki A, Hamashima Y, Hamayasu H, et al. Clinicopathological features of 15 occult and 178 clinical pancreatic ductal adenocarcinomas in 8339 autopsied elderly patients. Pancreas. 2016;45:234–40.
32. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol. 2005;6:437–45.
33. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007;56:1460–9.
34. Riall TS, Sheffield KM, Kuo Y-F, Townsend CM, Goodwin JS. Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. J Am Geriatr Soc. 2011;59:647–54.
35. Riall TS. What is the effect of age on pancreatic resection? Adv Surg. 2009;43:233–49.
36. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–5.
37. Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220:530–6.
38. Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995;222:426–34.
39. Turrini O, Paye F, Bachellier P, Sauvanet A, Sa Cunha A, Le Treut YP, et al. Pancreatectomy for adenocarcinoma in elderly patients: postoperative outcomes and long term results: a study of the French Surgical Association. Eur J Surg Oncol. 2013;39:171–8. Large study composing of more than 900 patients in Europe with pancreatic cancer undergoing pancreatectomy showing similar postoperative mortality and morbidity rates in patients of three age groups: <70, 70–79, and ≥80 years.
40. Oliveira-Cunha M, Malde DJ, Aldouri A, Morris-Stiff G, Menon KV, Smith AM. Results of pancreatic surgery in the elderly: is age a barrier? HPB. 2013;15:24–30.
41. Hayman TJ, Strom T, Springett GM, Balducci L, Hoffe SE, Meredith KL, et al. Outcomes of resected pancreatic cancer in patients age ≥70. J Gastrointest Oncol. 2015;6:498–504.
42. Beltrame V, Gruppo M, Pastorelli D, Pedrazzoli S, Merigliano S, Sperti C. Outcome of pancreaticoduodenectomy in octogenarians: single institution’s experience and review of the literature. J Visc Surg. 2015;152:279–84.
43. Hatzaras I, Schmidt C, Klemanski D, Muscarella P, Melvin WS, Ellison EC, et al. Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy. J Am Coll Surg. 2011;212:373–7.
44. Makary MA, Winter JM, Cameron JL, Campbell KA, Chang D, Cunningham SC, et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2006;10:347–56.
45. van der Geest LGM, Besselink MGH, van Gestel YRBM, Busch ORC, de Hingh IHJT, de Jong KP, et al. Pancreatic cancer surgery in elderly patients: balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol Stockh Swed. 2016;55:278–85.
46. Shah BC, Smith LM, Ullrich F, Are C. Discharge disposition after pancreatic resection for malignancy: analysis of national trends. HPB. 2012;14:201–8.
47. Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007;205:729–34.
48. Paniccia A, Hosokawa P, Henderson W, Schulick RD, Edil BH, McCarter MD, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015;150:701–10.
49. Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, et al. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1391–7.
50. Frakes JM, Strom T, Springett GM, Hoffe SE, Balducci L, Hodul P, et al. Resected pancreatic cancer outcomes in the elderly. J Geriatr Oncol. 2015;6:127–32.
51. Nagrial AM, Chang DK, Nguyen NQ, Johns AL, Chantrill LA, Humphris JL, et al. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer. 2014;110:313–9.
52. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.
53. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81. This trial established that adjuvant chemotherapy with gemcitabine provides survival benefit in the adjuvant setting.
54. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.
55. Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. ASCO Meet Abstr. 2016;34:LBA4006. This large randomized study showed superiority of adjuvant gemcitabine with capecitabine over gemcitabine alone and may change standard of care.
56. Murakawa M, Aoyama T, Katayama Y, Asari M, Sawazaki S, Yamaoku K, et al. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients. ASCO Meet Abstr. 2015;33:486.
57. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg Chic Ill 1960. 1985;120:899–903.
58. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–26.
59. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:504–12. This study showed that completion of all 6 cycles of adjuvant chemotherapy was more important than timing of adjuvant therapy.
60. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96:1183–90.
61. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3409–14.
62. Morizane C, Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, et al. Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients. Oncology. 2005;68:432–7.
63. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:4105–12.
64. Hammel P, Huguet F, Van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. ASCO Meet Abstr. 2013;31:LBA4003. This is the largest phase III trial to date comparing chemoradiotherapy to chemotherapy alone in locally advanced disease. This study showed no survival benefit with chemoradiation.
65. Kim CH, Ling DC, Wegner RE, Flickinger JC, Heron DE, Zeh H, et al. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiat Oncol Lond Engl. 2013;8:240.
66. Tozzi A, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol Lond Engl. 2013;8:148.
67. Alagappan M, Pollom EL, von Eyben R, Kozak MM, Aggarwal S, Poultsides GA, et al. Albumin and neutrophil-lymphocyte ratio (NLR) predict survival in patients with pancreatic adenocarcinoma treated with SBRT. Am J Clin Oncol. 2016. doi:10.1097/COC.0000000000000263.
68. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol. 2013;86:516–22. This is one of the larger series on the effectiveness of SBRT in locally advanced and borderline resectable pancreatic cancer.
69. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.
70. Katz MHG, Pisters PWT, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833–46.
71. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VWT, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2011;15:2059–69.
72. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466–73.
73. Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, et al. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery. 2015;158:1545–55. This study showed that older patients can derive similar benefits from neoadjuvant therapy compared to younger patients in resectable or borderline resectable pancreatic cancer.
74. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.
75. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266–74.
76. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP J Pancreas. 2012;13:497–501.
77. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153–9. Although effective, FOLFIRINOX has significant toxicity. This study described the experience with a modified FOLFIRINOX regimen in the neoadjuvant setting and showed that it is an effective and well-tolerated regimen.
78. Katz MHG, Shi Q, Ahmad SA, Herman JM, Marsh R de w, Collisson EA, et al. Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101. ASCO Meet Abstr. 2015;33:4008.
79. Varadhachary GR, Fleming JB, Crane CH, Fogelman DR, Shroff RT, Lee JE, et al. Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma. ASCO Meet Abstr. 2015;33:362.
80. Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107:djv132.
81. Kunzmann V, Herrmann K, Bluemel C, Kapp M, Hartlapp I, Steger U. Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer. Case Rep Oncol. 2014;7:648–55.
82. Trial to investigate intensified neoadjuvant chemotherapy in locally advanced pancreatic cancer—full text view—ClinicalTrials.gov [Internet]. [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02125136.
83. Tas F, Sen F, Keskin S, Kilic L, Yildiz I. Prognostic factors in metastatic pancreatic cancer: older patients are associated with reduced overall survival. Mol Clin Oncol. 2013;1:788–92.
84. Maréchal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36:e16–21.
85. Aldoss IT, Tashi T, Gonsalves W, Kalaiah RK, Fang X, Silberstein P, et al. Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer—a Veterans Affairs Cancer Registry analysis. J Geriatr Oncol. 2011;2:209–14.
86. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15:2403–13.
87. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
88. Alessandretti MB, Moreira RB, Brandao EP, Gomes JR, Amarante MPF, Lino ADR, et al. Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma. ASCO Meet Abstr. 2015;33:468. This study suggested that in older adults, the modified FOLFIRINOX regimen can be a reasonable option in advanced pancreatic cancer.
89. Efficacy and tolerance evaluation in FOLFIRINOX dose adjusted in elderly patients with a metastatic pancreatic cancer—full text view—ClinicalTrials.gov [Internet]. [cited 2016 Feb 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02143219.
90. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. This is a phase III randomized study which showed survival benefit of adding nab-paclitaxel to gemcitabine and is one of the most important recent trials, along with the FOLFIRINOX study by Conroy et al., to have changed the paradigm of treatment in advanced pancreatic cancer.
91. Giordano G, Vaccaro V, Lucchini E, Musettini G, Bertocchi P, Bergamo F, et al. Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): a “real-life” study. ASCO Meet Abstr. 2015;33:424.
92. Krishna K, Blazer MA, Wei L, Ahn DH, Wu CS-Y, Ciombor KK, et al. Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): a single-institution experience. ASCO Meet Abstr. 2015;33:366.
93. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:23–9.
94. Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet Lond Engl. 2016;387:545–57. This phase III study of 417 patients showed survival benefit of adding nanoliposomal irinotecan in combination with fluorouracil and folinic acid in patients previously treated with gemcitabine-based therapy. This study led to the approval of nanoliposomal irinotecan by the FDA for this indication.
95. Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113:989–95.
96. Rivera F, Gallego J, Guillen C, Benavides M, Lopez-Martin JA, Betticher DC, et al. PANOVA: a pilot study of TTFields concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma. ASCO Meet Abstr. 2016;34:269.
97. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1325–33.
98. Neoadjuvant/adjuvant GVAX pancreas vaccine (with CY) with or without nivolumab trial for surgically resectable pancreatic cancer—full text view—ClinicalTrials.gov [Internet]. [cited 2016 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02451982?term=pancreatic+pd1&rank=2.
99. Safety study of nivolumab with nab-paclitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage IIIb/IV non-small cell lung cancer or nab-paclitaxel in recurrent metastatic breast cancer—full text view—ClinicalTrials.gov [Internet]. [cited 2016 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02309177?term=pancreatic+pd1&rank=5.
100. Safety and immunological effect of pembrolizumab in resectable or borderline resectable pancreatic cancer—full text view—ClinicalTrials.gov [Internet]. [cited 2016 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02305186.
101. WHO | WHO’s cancer pain ladder for adults [Internet]. WHO. [cited 2016 Mar 3]. Available from: http://www.who.int/cancer/palliative/painladder/en/.
102. Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:3541–6.
103. Maire F, Hammel P, Ponsot P, Aubert A, O’Toole D, Hentic O, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol. 2006;101:735–42.
104. Nagaraja V, Eslick GD, Cox MR. Endoscopic stenting versus operative gastrojejunostomy for malignant gastric outlet obstruction-a systematic review and meta-analysis of randomized and non-randomized trials. J Gastrointest Oncol. 2014;5:92–8.
105. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.